Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Eilers

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Nature Genetics|March 8, 2016
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinomaXimena Bonilla, Laurent Parmentier, Bryan King, et al.
Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Nature Cell Biology|November 6, 2019
A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancerStefanie Schmidt, David Gay, Friedrich Wilhelm Uthe, et al.
Oncogene|January 22, 2025
Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancerMichaela Reissland, Oliver Hartmann, Saskia Tauch, et al.
Oncogene|October 24, 2024
USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancerMichaela Reissland, Oliver Hartmann, Saskia Tauch, et al.
Nature Cell Biology|March 14, 2026
Riboflavin metabolism shapes FSP1-driven ferroptosis resistanceVera Skafar, Izadora de Souza, Biplab Ghosh, et al.
Nature Communications|November 3, 2022
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingDario Zimmerli, Chiara S Brambillasca, Francien Talens, et al.
EMBO Molecular Medicine|July 12, 2023
LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastomaHamed Alborzinia, Zhiyi Chen, Umut Yildiz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Nature Genetics|March 8, 2016
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinomaXimena Bonilla, Laurent Parmentier, Bryan King, et al.
Expert Opinion on Drug Discovery|June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma projectLucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Nature Cell Biology|November 6, 2019
A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancerStefanie Schmidt, David Gay, Friedrich Wilhelm Uthe, et al.
Oncogene|January 22, 2025
Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancerMichaela Reissland, Oliver Hartmann, Saskia Tauch, et al.
Oncogene|October 24, 2024
USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancerMichaela Reissland, Oliver Hartmann, Saskia Tauch, et al.
Nature Cell Biology|March 14, 2026
Riboflavin metabolism shapes FSP1-driven ferroptosis resistanceVera Skafar, Izadora de Souza, Biplab Ghosh, et al.
Nature Communications|November 3, 2022
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingDario Zimmerli, Chiara S Brambillasca, Francien Talens, et al.
EMBO Molecular Medicine|July 12, 2023
LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastomaHamed Alborzinia, Zhiyi Chen, Umut Yildiz, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2020
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe NeuroblastomaLucas Moreno, Giuseppe Barone, Steven G DuBois, et al.
The Journal of Clinical Investigation|October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaEvon Poon, Tong Liang, Yann Jamin, et al.
Pageof 17